The FDA facility inspection assignment is a tangible catalyst — a successful inspection would clear the path for NDA resubmission and potential approval. Monitor for completion of the inspection and any subsequent FDA communication. The narrowed net loss is non-operational (warrant liability gain); the underlying cash burn rate is increasing, so the stock will trade on OLC regulatory milestones, not quarterly financials.
Price Chart
Executive Summary
Unicycive Therapeutics reported Q2 2026 results with a net loss of $(1.7) million ($(0.06)/share), significantly narrower than the $(6.5) million loss in Q2 2025, driven by a $7.98 million non-cash gain from warrant liability revaluation. The key event is the FDA's assignment of a facility inspection to the third-party manufacturing vendor for OLC, a positive procedural step after receiving a Complete Response Letter in June 2026, but the NDA resubmission timeline remains contingent on a successful inspection outcome.
Key Financial Metrics
Key Facts
- Net loss narrowed to $(1.7)M in Q2 2026 from $(6.5)M in Q2 2025, primarily due to a $7.98M non-cash gain from change in fair value of warrant liability.
- FDA assigned a facility inspection to the third-party manufacturing vendor for OLC, a step toward potential NDA resubmission after the June 2026 CRL.
- Cash, cash equivalents, and marketable securities totaled $61.4M as of June 30, 2026, with expected runway into 2027.
- Operating expenses (R&D + G&A) rose to $10.1M from $7.0M year-over-year, driven by increased stock-based compensation and commercial launch preparation costs.
- The company received a CRL in June 2026 citing the same third-party manufacturing deficiencies as a prior CRL in June 2025; no clinical safety or efficacy concerns were raised.
Financial Impact
Net loss improved by $4.7M year-over-year, but operating cash burn increased to $10.1M vs $7.0M. Cash runway into 2027 provides ~12-18 months of liquidity.
Risk Factors
- Third-party manufacturing facility inspection may fail, delaying NDA resubmission indefinitely.
- Cash burn is increasing ($10.1M operating expenses in Q2 vs $7.0M a year ago), potentially requiring future capital raises before OLC generates revenue.
- OLC has now received two CRLs for the same manufacturing issue, raising execution risk on the vendor's remediation timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-088061 |
| Document: ea0301699-8k_unicycive.htm | 0001213900-26-088061 |
| Document: 0001213900-26-088061-index-headers.html | 0001213900-26-088061 |
| Document: 0001213900-26-088061-index.html | 0001213900-26-088061 |
| Document: 0001213900-26-088061.txt | 0001213900-26-088061 |
| 8-K Data (Synthetic) | 0001213900-26-088061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 3 | $4.22 | awaiting T+60 | — | $3.68 (−12.68%) |
Sep 29, 2026 28d ago | 8-K | $4.55 | awaiting T+60 | — | $3.68 (−19.01%) |
Aug 12, 2026 10w ago | 8-K | $5.39 | awaiting T+60 | — | $3.68 (−31.63%) |
Jul 2, 2026 16w ago | 8-K | $5.73 $4.81 | ▼ −16.06% | ▼ −19.06% | $3.68 (−35.69%) |
Jun 22, 2026 18w ago | DEFA14A | $7.87 $4.71 | ▼ −40.15% | ▼ −41.90% | $3.68 (−53.18%) |
Jun 16, 2026 19w ago | EFFECT | $7.17 $5.31 | ▲ +25.94% | ▲ +26.94% | $3.68 (+48.61%) |
Jun 5, 2026 20w ago | S-3 | $6.66 $5.05 | ▲ +24.17% | ▲ +27.23% | $3.68 (+44.67%) |
May 12, 2026 24w ago | 8-K | $8.17 $5.05 | ▼ −38.19% | ▼ −42.57% | $3.68 (−54.90%) |
May 12, 2026 24w ago | Press Release | $8.17 $5.05 | ▲ +38.19% | ▲ +42.57% | $3.68 (+54.90%) |
Apr 6, 2026 29w ago | 8-K | $6.62 $5.28 | ▼ −20.24% | ▼ −33.71% | $3.68 (−44.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers